Avadel Pharmaceuticals plc (AVDL)

In October 2025, a bidding war for Avadel ensued between Irish Alkermes plc and Danish Lundbeck, with Alkermes making an offer of up to $2.1 billion, and on January 12, 2026, Avadel Pharmaceuticals plc announced that its shareholders approved the proposed acquisition by Alkermes plc. Between October and November 2025, several analysts downgraded Avadel Pharmaceuticals' stock. In November 2025, Citadel Group disclosed a 1.13% ownership position in Avadel Pharmaceuticals plc, which included both owned and controlled shares, and shares through stock-settled derivatives, and also disclosed a short position of 1.12% in Avadel. As of January 9, 2026, AVDL stock had risen by 0.05% compared to the previous week and 0.56% over the last month, and over the last year, Avadel Pharmaceuticals plc showed a 166.75% increase in its stock price.

There is no explicit information indicating demand seasonality for Avadel Pharmaceuticals Plc's products and services. Demand is primarily driven by patient uptake, adherence, and market penetration strategies rather than seasonal fluctuations.

Avadel Pharmaceuticals Plc is focused on developing and commercializing treatments for sleep disorders, particularly narcolepsy. Its core business revolves around addressing unmet medical needs in chronic conditions, with a significant focus on sleep medicine. Its flagship product is LUMRYZ, an extended-release oral suspension approved by the FDA as the first and only once-at-bedtime oxybate for treating cataplexy or excessive daytime sleepiness in adults with narcolepsy. The company also leverages proprietary drug delivery technologies, including MICROPUMP, LIQUITIME, and MEDUSA.

Avadel Pharmaceuticals Plc is headquartered in Dublin, Ireland, and maintains operations in St. Louis, Missouri, in the United States, and Lyon, France. It sells its products in the US and Ireland.

Avadel Pharmaceuticals Plc has maintained an established brand reputation for delivering high-quality products and services within the pharmaceutical industry. The company's reputation has been positively influenced by the ongoing success and adoption of its flagship product, LUMRYZ, for narcolepsy treatment. The recent approval by shareholders of the acquisition by Alkermes plc in January 2026 is also a significant event that could reflect positively on the company's strategic direction and value.

Avadel Pharmaceuticals plc has a significant institutional ownership, with 69.19% of its stock held by institutions including Janus Henderson Group Plc, BlackRock, Inc., and Vanguard Group Inc. Company insiders hold 5.20% of the stock.